Is IHE a good investment?

iShares U.S. Pharmaceuticals ETF (IHE) is a healthcare and biotech ETF. As of September 11, 2026, ETF Copilot scores IHE 6.4 out of 10 — highest on Growth (8.5), lowest on Valuation (4.1). It trades at 27.3 times earnings, against its own median of 22.5. Its ten largest holdings are 78% of the fund.

Updated September 11, 2026

How is IHE rated? ETF Copilot scores iShares U.S. Pharmaceuticals ETF (IHE) 6.4 out of 10

As of September 11, 2026, ETF Copilot scores iShares U.S. Pharmaceuticals ETF (IHE) 6.4 out of 10 overall.

ETF Copilot scores (0–10 scale, higher is better):

Overall: 6.4 / 10
Growth: 8.5 / 10
Valuation: 4.1 / 10
Risk: 6.6 / 10
Quality: 7.1 / 10
Return: 5.1 / 10

What is IHE's expense ratio? 0.37% a year

As of September 11, 2026, IHE charges 0.37% a year, yields 1.83% and holds $1.7B in assets across 56 positions.

iShares U.S. Pharmaceuticals ETF (IHE) — cost, income and size
Measure	IHE
Expense ratio	0.37%
Dividend yield	1.83%
Assets under management	$1.7B
Holdings	56

Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.

What stands out in IHE's data

U.S. pharmaceutical manufacturers, held through a market-cap-weighted index.

Trades near the same price as the typical health-care fund — no valuation edge, just the sector's own prospects.

Trailing P/E multiple of 27.3x sits in line with the category median of 27.2x, and its top 10 holdings make up 77.5% of assets.

A sector-specific position in drug makers, for portfolios that want targeted health-care exposure.

Why did IHE move this week? It fell 4.1% in the week to September 11, 2026 — Johnson & Johnson and Eli Lilly drove it

IHE fell 4.1% in the week to September 11, 2026. The holdings that moved it most were Johnson & Johnson (−4.6%), Eli Lilly (−3.8%) and Royalty Pharma (−8.2%); Axsome Therapeutics (+6.0%) pushed the other way.

Is IHE expensive right now? It trades at 27.3 times earnings, against its own median of 22.5

As of September 11, 2026, IHE is more expensive than 89% of its own 114 monthly readings since 2017 — 102 of those months were cheaper than today.

Trailing twelve-month, computed by ETF Copilot from the fund's holdings rather than quoted from a data provider, and rebuilt nightly.

What's inside IHE?

What's inside IHE: Size (Large 63%, Mid 23%, Small 15%); Geography (International 4%, US 96%).

What are IHE's top holdings? The ten largest are 78% of the fund

More concentrated than 98% of Healthcare & Biotech ETFs.

Half of IHE's weight sits in its 4 largest positions, and once those weights are taken into account it behaves like 9 equally weighted holdings.

Cite this

ETF Copilot, “iShares U.S. Pharmaceuticals ETF (IHE) scores and holdings analysis”, as of September 11, 2026.
https://etf-copilot.com/etf/ihe